Häftad, Engelska, 2022

Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics

2068 kr

Beställningsvara. Skickas inom 11-20 vardagar. Fri frakt över 249 kr.

Beskrivning

Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics provides a review of the basic anatomy, physiology, biochemistry and pathology of the eye with a focus drug therapy, drug delivery and use of therapeutic medical miniature devices. An understanding of the pharmacological actions of drugs acting on the eye requires the student and health care practitioner to learn additional principles in basic and clinical sciences that are unique to this organ. As a sensory organ, the eye is relatively inaccessible to the systemic circulation due to the blood-vitreous, blood-aqueous and blood-retinal barriers. Consequently, the administration of drugs for therapeutic effects in the eye necessitates an understanding of physico-chemical properties of the molecules and pharmacokinetic principles involved in the access to its site of action via topical, intracameral and intravitreal administration. This book includes information on the general principles of pharmacokinetics and pharmacodynamics of drugs as it pertains to the eye and in combating ocular disorders and diseases. Using a disease-themed approach, the book discusses basic and clinical pharmacological principles involved in the therapy of these diseases including the ocular side effect of systemically-administered drugs, drugs used in ophthalmic surgery and miscellaneous agents, the therapeutic utility of biologics, drug conjugates, combination products, gene and cellular therapy are also covered. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics is useful as a primary and secondary source of reference for up-to-date information about the pharmacological mechanisms of action, pharmacokinetics, side effects, drug-drug interactions and therapeutic indications of drugs for pharmacologists, pharmaceutical scientists, students in the health care disciplines (nursing, pharmacy, optometry, medical), and practitioners in optometry and ophthalmology.

Explains the mechanisms of action, side-effects and therapeutic uses of drugs, biologics, miniature devices, gene and cellular therapies for the eye
Provides a comprehensive review of the anatomy, physiology, biochemistry, pharmacology, microbiology, genetics and pathology of parts of the eye involved in drug therapy to combat eye disorders and diseases
Explores the pharmacological and clinical basis of drugs, drug conjugates, combination products used in the treatment of anterior and posterior segment diseases

Produktinformation

Utgivningsdatum: 2022-07-25
Mått: 191 x 235 x 34 mm
Vikt: 450 g
Format: Häftad
Språk: Engelska
Antal sidor: 672
Förlag: Elsevier Science
ISBN: 9780128192917

Utforska kategorier

Mer om författaren

Sunny Ohia is a Professor of Pharmacology in the College of Pharmacy and Health Sciences at Texas Southern University. Dr. Ohia has over 38 years of experience in higher education having served as a member of faculty in five universities in Canada and the United States. He holds other academic appointments as adjunct professor of ophthalmology and visual sciences at the University of Nebraska Medical Center, Omaha and as an adjunct professor of integrative biology and pharmacology at the University of Texas Health Sciences Center in Houston. Dr. Ohia is a Fellow of the Nigerian Academy of Science and a Fellow of the Association for Research in Vision and Ophthalmology. He's authored over 250 original papers, book chapters, books, and abstracts and, holds three U.S. and five international Patents for his scientific work. Najam Sharif, Ph.D., D.Sc., FARVO, FBPhS, FAOPT is a graduate of Southampton University, England where he received his BSc (Joint Honors: Biochemistry and Physiology), PhD (Neuroscience), and DSc (by thesis; Ophthalmology). He has been in the pharmaceutical industry for >34-years holding leadership positions of increasing scope and responsibility at Parke-Davis/Warner-Lambert (Pfizer), Syntex Research (Roche), Alcon-Novartis, and is currently at Santen Inc (Vice President, Global Alliances and External Research, Ophthalmology Innovation Center, R&D Division). He contributed to the discovery/development and US FDA approvals of multiple drugs to treat glaucoma/ocular hypertension and ocular allergies. He was recently elected as a Gold Fellow of ARVO, Fellow of British Pharmacological Society (BPS), and a Trustee of Assoc. Ocular Pharmacology & Therapeutics. He was the recipient of the inaugural Dr. Roger Vogel award for pharmaceutical research presented by the ARVO Foundation (2014), the "Sir James Black Award for contributions to drug discovery from BPS (2017), and the awardee of the Ernst H Barany Prize for exemplary contributions to ocular pharmacology (2020). He was also elected to the Board of Directors and the Scientific Advisory Board of The Glaucoma Foundation (2020). He serves on the editorial boards of numerous scientific journals, and is an Adjunct Professor and Thesis advisor at several global universities.

Betyg & recensioner

0 recensioner

Inga recensioner tillgängliga.